Kurs & Likviditet
Kalender
2024-10-29 | Kvartalsrapport 2024-Q3 |
2024-10-15 | Halvårsutdelning ORNBV 0.81 |
2024-10-15 | Halvårsutdelning ORNAV 0.81 |
2024-08-08 | Kvartalsrapport 2024-Q2 |
2024-04-25 | Kvartalsrapport 2024-Q1 |
2024-03-21 | Halvårsutdelning ORNBV 0.81 |
2024-03-21 | Halvårsutdelning ORNAV 0.81 |
2024-03-20 | Årsstämma 2024 |
2024-02-13 | Bokslutskommuniké 2023 |
2023-10-26 | Kvartalsrapport 2023-Q3 |
2023-07-17 | Kvartalsrapport 2023-Q2 |
2023-04-27 | Kvartalsrapport 2023-Q1 |
2023-03-23 | Ordinarie utdelning ORNAV 1.60 EUR |
2023-03-23 | Ordinarie utdelning ORNBV 1.60 EUR |
2023-03-22 | Årsstämma 2023 |
2023-02-09 | Bokslutskommuniké 2022 |
2022-10-20 | Kvartalsrapport 2022-Q3 |
2022-07-15 | Kvartalsrapport 2022-Q2 |
2022-04-28 | Kvartalsrapport 2022-Q1 |
2022-03-24 | Ordinarie utdelning ORNAV 1.50 EUR |
2022-03-24 | Ordinarie utdelning ORNBV 1.50 EUR |
2022-03-23 | Årsstämma 2022 |
2022-02-10 | Bokslutskommuniké 2021 |
2021-10-20 | Kvartalsrapport 2021-Q3 |
2021-07-19 | Kvartalsrapport 2021-Q2 |
2021-04-27 | Kvartalsrapport 2021-Q1 |
2021-03-26 | Ordinarie utdelning ORNAV 1.50 EUR |
2021-03-26 | Ordinarie utdelning ORNBV 1.50 EUR |
2021-03-25 | Årsstämma 2021 |
2021-02-09 | Bokslutskommuniké 2020 |
2020-10-21 | Kvartalsrapport 2020-Q3 |
2020-07-17 | Kvartalsrapport 2020-Q2 |
2020-05-07 | Ordinarie utdelning ORNBV 1.50 EUR |
2020-05-07 | Ordinarie utdelning ORNAV 1.50 EUR |
2020-05-06 | Årsstämma 2020 |
2020-04-28 | Kvartalsrapport 2020-Q1 |
2020-03-26 | Ordinarie utdelning ORNBV 1.50 EUR |
2020-02-05 | Bokslutskommuniké 2019 |
2019-10-23 | Kvartalsrapport 2019-Q3 |
2019-07-17 | Kvartalsrapport 2019-Q2 |
2019-04-25 | Kvartalsrapport 2019-Q1 |
2019-03-27 | Ordinarie utdelning ORNAV 1.50 EUR |
2019-03-27 | Ordinarie utdelning ORNBV 1.50 EUR |
2019-03-26 | Årsstämma 2019 |
2019-02-06 | Bokslutskommuniké 2018 |
2018-10-24 | Kvartalsrapport 2018-Q3 |
2018-07-18 | Kvartalsrapport 2018-Q2 |
2018-04-24 | Kvartalsrapport 2018-Q1 |
2018-03-21 | Ordinarie utdelning ORNAV 1.45 EUR |
2018-03-21 | Ordinarie utdelning ORNBV 1.45 EUR |
2018-03-20 | Årsstämma 2018 |
2018-02-07 | Bokslutskommuniké 2017 |
2017-10-26 | Kvartalsrapport 2017-Q3 |
2017-07-19 | Kvartalsrapport 2017-Q2 |
2017-05-18 | Kapitalmarknadsdag 2017 |
2017-04-26 | Kvartalsrapport 2017-Q1 |
2017-03-23 | Ordinarie utdelning ORNAV 1.35 EUR |
2017-03-23 | Bonusutdelning ORNAV 0.2 |
2017-03-23 | Bonusutdelning ORNBV 0.2 |
2017-03-23 | Ordinarie utdelning ORNBV 1.35 EUR |
2017-03-22 | Årsstämma 2017 |
2017-02-08 | Bokslutskommuniké 2016 |
2016-10-25 | Kvartalsrapport 2016-Q3 |
2016-07-19 | Kvartalsrapport 2016-Q2 |
2016-04-27 | Kvartalsrapport 2016-Q1 |
2016-03-23 | Ordinarie utdelning ORNBV 1.30 EUR |
2016-03-23 | Ordinarie utdelning ORNAV 1.30 EUR |
2016-03-22 | Årsstämma 2016 |
2016-02-02 | Bokslutskommuniké 2015 |
2015-10-27 | Kvartalsrapport 2015-Q3 |
2015-07-28 | Kvartalsrapport 2015-Q2 |
2015-05-26 | Kapitalmarknadsdag 2015 |
2015-04-29 | Kvartalsrapport 2015-Q1 |
2015-03-25 | Ordinarie utdelning ORNBV 1.30 EUR |
2015-03-25 | Ordinarie utdelning ORNAV 1.30 EUR |
2015-03-24 | Årsstämma 2015 |
2015-02-04 | Bokslutskommuniké 2014 |
2014-10-21 | Kvartalsrapport 2014-Q3 |
2014-07-29 | Kvartalsrapport 2014-Q2 |
2014-04-29 | Kvartalsrapport 2014-Q1 |
2014-03-26 | Ordinarie utdelning ORNAV 1.25 EUR |
2014-03-26 | Ordinarie utdelning ORNBV 1.25 EUR |
2014-03-25 | Årsstämma 2014 |
2014-02-04 | Bokslutskommuniké 2013 |
2013-10-22 | Kvartalsrapport 2013-Q3 |
2013-07-30 | Kvartalsrapport 2013-Q2 |
2013-04-23 | Kvartalsrapport 2013-Q1 |
2013-03-20 | Ordinarie utdelning ORNAV 1.30 EUR |
2013-03-20 | Ordinarie utdelning ORNBV 1.30 EUR |
2013-03-19 | Årsstämma 2013 |
2013-02-05 | Bokslutskommuniké 2012 |
2012-10-23 | Kvartalsrapport 2012-Q3 |
2012-07-31 | Kvartalsrapport 2012-Q2 |
2012-05-24 | Kapitalmarknadsdag 2012 |
2012-04-24 | Kvartalsrapport 2012-Q1 |
2012-03-21 | Ordinarie utdelning ORNAV 1.30 EUR |
2012-03-21 | Bonusutdelning ORNAV 0.12 |
2012-03-21 | Ordinarie utdelning ORNBV 1.30 EUR |
2012-03-21 | Bonusutdelning ORNBV 0.12 |
2012-03-20 | Årsstämma 2012 |
2012-02-07 | Bokslutskommuniké 2011 |
2011-10-25 | Kvartalsrapport 2011-Q3 |
2011-08-02 | Kvartalsrapport 2011-Q2 |
2011-04-27 | Kvartalsrapport 2011-Q1 |
2011-04-01 | Bonusutdelning ORNBV 0.06 |
2011-04-01 | Bonusutdelning ORNAV 0.06 |
2011-04-01 | Ordinarie utdelning ORNAV 1.20 EUR |
2011-04-01 | Ordinarie utdelning ORNBV 1.20 EUR |
2011-03-31 | Årsstämma 2011 |
2011-02-09 | Bokslutskommuniké 2010 |
2010-10-26 | Kvartalsrapport 2010-Q3 |
2010-08-10 | Kvartalsrapport 2010-Q2 |
2010-04-27 | Kvartalsrapport 2010-Q1 |
2010-03-25 | Ordinarie utdelning ORNBV 1.00 EUR |
2010-03-25 | Bonusutdelning ORNBV 0.1 |
2010-03-25 | Bonusutdelning ORNAV 0.1 |
2010-03-25 | Ordinarie utdelning ORNAV 1.00 EUR |
2009-03-24 | Ordinarie utdelning ORNAV 0.95 EUR |
2009-03-24 | Ordinarie utdelning ORNBV 0.95 EUR |
2008-03-26 | Ordinarie utdelning ORNBV 1.00 EUR |
2007-04-03 | Ordinarie utdelning ORNAV 1.00 EUR |
2007-04-03 | Ordinarie utdelning ORNBV 1.00 EUR |
2006-03-22 | Ordinarie utdelning ORNBV 0.85 EUR |
2005-03-22 | Ordinarie utdelning ORNAV 0.55 EUR |
2005-03-22 | Ordinarie utdelning ORNBV 0.55 EUR |
2004-09-15 | Bonusutdelning ORNAV 2.14 |
2004-09-15 | Bonusutdelning ORNBV 2.14 |
2004-03-23 | Ordinarie utdelning ORNAV 1.60 EUR |
2004-03-23 | Ordinarie utdelning ORNBV 1.60 EUR |
2003-12-12 | Bonusutdelning ORNAV 1.5 |
2003-12-12 | Bonusutdelning ORNBV 1.5 |
2003-03-23 | Ordinarie utdelning ORNAV 0.93 EUR |
2003-03-23 | Ordinarie utdelning ORNBV 0.93 EUR |
2002-04-16 | Ordinarie utdelning ORNBV 1.10 EUR |
2002-04-16 | Ordinarie utdelning ORNAV 1.10 EUR |
2001-03-30 | Ordinarie utdelning ORNAV 1.20 EUR |
2001-03-30 | Ordinarie utdelning ORNBV 1.20 EUR |
2000-03-31 | Ordinarie utdelning ORNAV 1.18 EUR |
2000-03-31 | Ordinarie utdelning ORNBV 1.18 EUR |
1999-07-28 | Bonusutdelning ORNBV 13.46 |
1999-07-28 | Bonusutdelning ORNAV 13.46 |
1999-04-09 | Ordinarie utdelning ORNAV 6.50 EUR |
1999-04-09 | Ordinarie utdelning ORNBV 6.50 EUR |
1998-04-21 | Ordinarie utdelning ORNBV 7.50 EUR |
1998-04-21 | Ordinarie utdelning ORNAV 7.50 EUR |
1997-04-22 | Ordinarie utdelning ORNAV 5.00 EUR |
1997-04-22 | Ordinarie utdelning ORNBV 5.00 EUR |
1996-04-23 | Ordinarie utdelning ORNBV 4.00 EUR |
1996-04-23 | Ordinarie utdelning ORNAV 4.00 EUR |
Beskrivning
Land | Finland |
---|---|
Lista | Large Cap Helsinki |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
ORION CORPORATION
INSIDE INFORMATION / STOCK EXCHANGE RELEASE
17 FEBRUARY 2022 at 23.32 EET
Orion’s collaboration partner Bayer upgrades estimate on Nubeqa®’s peak sales potential
Orion’s collaboration partner Bayer has upgraded estimate on Nubeqa®’s (darolutamide) peak sales potential. According to Bayer’s new estimate, Nubeqa’s annual global peak sales could exceed EUR 3 billion. Earlier Bayer has anticipated that Nubeqa’s annual global peak sales could exceed EUR 1 billion.
Bayer holds global commercial rights to darolutamide and Orion is entitled to receive annually tiered royalties on global darolutamide sales. The total annual royalty rate is approximately 20% including product sales to Bayer. Initially the total annual royalty rate will be slightly lower, and as sales increase, the total annual royalty rate will increase. Orion manufactures the product for global markets and co-promotes the product in Europe with Bayer.
In addition to royalties, Orion is entitled to receive progressive one-off milestone payments from Bayer that may total EUR 280 million, depending on the future sales development of Nubeqa.
Orion Corporation
Timo Lappalainen President and CEO | Olli Huotari SVP, Corporate Functions |
Contact person:
Tuukka Hirvonen, Orion Investor Relations
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.